
Biomednewsbreaks - Soligenix Inc. (NASDAQ: SNGX) Moves Forward To Strengthen The Case For Hybryte(TM)
(MENAFN- Investor Brand Network) Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage cutaneous T-cell lymphoma …